- Clioquinol-loaded UiO-66(Ce) integrates Ce(III)/Ce(IV) ROS scavenging with CQ metal chelation to target multiple Alzheimer's disease pathological factors.
- In PC-12 Aβ-Cu2+ model the hybrid showed biocompatibility, reduced intracellular ROS, improved cell viability and altered Aβ aggregation.
- Compared with individual components UiO-66(Ce)-CQ demonstrated enhanced overall performance and provides a preliminary in vitro proof of concept for dual-function MOF therapeutics.
ACS Appl Bio Mater. 2026 Aug 17;9(16):7629-7636. doi: 10.1021/acsabm.6c01023.
ABSTRACT
Alzheimer’s disease (AD) is a major neurodegenerative disorder associated with amyloid-β (Aβ) aggregation and oxidative stress, often linked to metal ion dyshomeostasis. In this study, we developed a clioquinol (CQ)-loaded UiO-66(Ce), a cerium-based metal-organic framework (MOF), as a potential dual-functional platform. The system is designed to combine reactive oxygen species (ROS) scavenging via Ce(III)/Ce(IV) redox cycling with the metal-chelating capability of CQ, aiming to modulate multiple AD-related pathological factors. The material was synthesized and characterized, and its biological performance was preliminarily evaluated in PC-12 cells using an Aβ-Cu2+ model system. The results suggest that UiO-66(Ce)-CQ exhibits acceptable biocompatibility and is associated with reduced intracellular ROS levels, improved cell viability, and modulation of Aβ aggregation behavior. Compared with its individual components, UiO-66(Ce)-CQ showed enhanced overall performance under the tested conditions. While this study is limited to initial in vitro evaluation, the findings provide a preliminary proof of concept for integrating ROS-scavenging and metal-chelating functionalities within a single MOF-based platform, which may offer a potential strategy for AD-related applications.
PMID:42606055 | DOI:10.1021/acsabm.6c01023
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
